Loading clinical trials...

Exploring Clinical Trial Experiences of People With Leiomyosarcoma | Clinical Trials | Clareo Health

UNKNOWN

Exploring Clinical Trial Experiences of People With Leiomyosarcoma

An In Depth Study Investigating The Experiences of Patients In Leiomyosarcoma Clinical Trials

NCT05548179•Power Life Sciences Inc.

Summary

Clinical study participation has historically been heavily biased toward specific demographics. Several people will be invited to enroll in this study so that it may collect a variety of data about leiomyosarcoma clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. People with leiomyosarcoma who are invited to take part in medical research will benefit from the analysis of the data.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient has self-identified as planning to enroll in an interventional clinical trial
•Patient has been diagnosed with leiomyosarcoma
•Patient is a minimum of 18 years or older

Exclusion Criteria

•Patient does not understand, sign, and return consent form
•Inability to perform regular electronic reporting
•Patient is pregnant
•ECOG score of 4

Key Dates

Start Date

October 1, 2023

Primary Completion Date

October 1, 2024

Completion Date

October 1, 2025

Last Updated

March 6, 2023

Enrollment

500

ESTIMATED participants

Conditions

Leiomyosarcoma

Contacts

Michael B Gill

CONTACT

4159004227 bask@withpower.com

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290

Leiomyosarcoma

View study

RECRUITING

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

NCT07432932

SarcomaSarcoma, Leiomyo-, Adult+10 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Exploring Clinical Trial Experiences of People With Leiomyosarcoma

Inclusion Criteria

Exclusion Criteria

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy